Endocrine Abstracts

People with type 1 diabetes are at increased risks of developing other autoimmune conditions. This includes coeliac and autoimmune thyroid disease. The prevalence of coeliac disease is 1 in 100 people however in type 1 diabetes the prevalence increases up to 9%. As these cohort of patients are at a higher risk it is crucial to screen for coeliac disease. The American diabetes association (ADA) guidelines recommend screening for coeliac disease soon after diagnosis and within 5 years thereafter. The aim of this audit was to determine if adult patients with type 1 diabetes were screened for coeliac disease within 5 years of diagnosis as per the ADA guidelines_. This retrospective study occurred in October 2023. All patients with type 1 diabetes attending Sligo University Hospital were included in the study. Data including demographics, duration of diabetes and date of last coeliac screening was obtained from Prowellness diabetes database. Coeliac screening compromised of Anti-tTG and IgA. 584 patients were included in the study. 56% were males and remaining 44% females. Ages ranged from 18-79 with average age of 28. 20% (n = 121) had coeliac screening performed within the time period 2022 to 2023. 2.4% (n = 14) had screening done within 5 years of diagnosis of Type 1 diabetes. Of the 14, 1 patient tested positive for coeliac disease within 4 months of diagnosis of type 1 diabetes. Studies have shown that diagnosis of coeliac disease in type 1 diabetes usually occurs within 5 years. Results of this audit highlights poor screening for coeliac disease within 5 years of diagnosis in Type 1 diabetes and need to increase physician awareness. Coeliac disease can complicate treatment of type 1 diabetes due to increase morbidity and mortality. Further research is warranted to determine necessity for screening beyond first 5 years of diagnosis.